MX2010007269A - Derivado de 17-(1´-propenil)-17-3´-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen. - Google Patents

Derivado de 17-(1´-propenil)-17-3´-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen.

Info

Publication number
MX2010007269A
MX2010007269A MX2010007269A MX2010007269A MX2010007269A MX 2010007269 A MX2010007269 A MX 2010007269A MX 2010007269 A MX2010007269 A MX 2010007269A MX 2010007269 A MX2010007269 A MX 2010007269A MX 2010007269 A MX2010007269 A MX 2010007269A
Authority
MX
Mexico
Prior art keywords
derivative
derivatives
oxidoestra
propenyl
relates
Prior art date
Application number
MX2010007269A
Other languages
English (en)
Inventor
Sven Ring
Ulrich Klar
Rolf Bohlmann
Jan Huebner
Katja Prelle
Steffen Borden
Joachim Kuhnke
Frederik Menges
Thomas Frenzel
Hans Peter Muhn
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010007269(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2010007269A publication Critical patent/MX2010007269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/001—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class spiro-linked
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a derivados de 17-(1'-propenil)-17-3'-oxid oestra-4-en-3-ona que tienen la fórmula química general I, en la cual Z, R4, R6a, R6b, R7, R15, R16a, R16b, y R18 tienen los valores que se indican en la reivindicación 1, así como sus solvatos, hidratos y sales, incluyendo todos los estereoisómeros de estos compuestos. La invención también se refiere al uso de estos derivados para la preparación de un medicamento para la contracepción oral y para el tratamiento de trastornos pre, peri y posmenopáusicos y a medicamentos que contienen tales derivados, particularmente su uso en las indicaciones mencionadas. Los derivados de la invención presentan un efecto gestagénico y en casos preferidos, adicionalmente un efecto antimineralcorticoide y neutro a ligeramente androgénico. (ver fórmula (I)).
MX2010007269A 2007-12-29 2008-12-23 Derivado de 17-(1´-propenil)-17-3´-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen. MX2010007269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007063500A DE102007063500A1 (de) 2007-12-29 2007-12-29 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
PCT/EP2008/011161 WO2009083268A2 (de) 2007-12-29 2008-12-23 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-derivat, dessen verwendung und das derivat enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
MX2010007269A true MX2010007269A (es) 2010-10-15

Family

ID=40679349

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007269A MX2010007269A (es) 2007-12-29 2008-12-23 Derivado de 17-(1´-propenil)-17-3´-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen.

Country Status (23)

Country Link
US (1) US9034856B2 (es)
EP (1) EP2238147B1 (es)
JP (1) JP5600069B2 (es)
KR (1) KR20100102190A (es)
CN (1) CN101918426A (es)
AR (1) AR069964A1 (es)
AU (1) AU2008342912A1 (es)
BR (1) BRPI0822068A2 (es)
CA (1) CA2710934C (es)
CL (1) CL2008003885A1 (es)
CR (1) CR11541A (es)
DE (1) DE102007063500A1 (es)
DO (1) DOP2010000201A (es)
EC (1) ECSP10010316A (es)
ES (1) ES2397985T3 (es)
IL (1) IL206381A0 (es)
MX (1) MX2010007269A (es)
PA (1) PA8807901A1 (es)
PE (1) PE20091185A1 (es)
TW (1) TW200940562A (es)
UY (1) UY31582A1 (es)
WO (1) WO2009083268A2 (es)
ZA (1) ZA201005397B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
CH559220A5 (es) 1970-03-06 1975-02-28 Ciba Geigy Ag
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3702383A1 (de) 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4232521A1 (de) 1992-09-22 1994-03-24 Schering Ag Gestagen wirksame 4,5;11,12-Estradiene, Verfahren zu ihrer Herstellung, diese Estradiene enthaltende Arzneimittel sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
PA8807901A1 (es) 2009-07-23
EP2238147B1 (de) 2012-10-24
AR069964A1 (es) 2010-03-03
WO2009083268A2 (de) 2009-07-09
AU2008342912A1 (en) 2009-07-09
IL206381A0 (en) 2010-12-30
CA2710934A1 (en) 2009-07-09
DE102007063500A1 (de) 2009-07-02
UY31582A1 (es) 2009-08-03
EP2238147A2 (de) 2010-10-13
ECSP10010316A (es) 2010-08-31
ZA201005397B (en) 2012-01-25
ES2397985T3 (es) 2013-03-12
DOP2010000201A (es) 2010-07-15
JP2011507925A (ja) 2011-03-10
PE20091185A1 (es) 2009-09-06
CR11541A (es) 2010-08-05
CA2710934C (en) 2015-07-21
TW200940562A (en) 2009-10-01
CN101918426A (zh) 2010-12-15
WO2009083268A3 (de) 2009-09-24
JP5600069B2 (ja) 2014-10-01
CL2008003885A1 (es) 2010-05-07
US20100317632A1 (en) 2010-12-16
BRPI0822068A2 (pt) 2015-06-23
US9034856B2 (en) 2015-05-19
KR20100102190A (ko) 2010-09-20

Similar Documents

Publication Publication Date Title
MY180812A (en) 4'-o-substituted isoindoline derivattives and compositions comprising and methods of using the same
MD3551622T2 (ro) Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
TW200602036A (en) Diphenylazetidone derivates
MX347987B (es) Derivados de quinazolinona 6-,7-, u 8-sustituidos y composiciones que los comprenden y metodos para usar los mismos.
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
MX2008002765A (es) Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MX2009006689A (es) Inhibidores viia de los factores macrociclicos utiles como anticoagulantes.
TW200726747A (en) Chemical compounds
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
MX2010004682A (es) Metodo de supresion de hormonas en humanos.
TW200730493A (en) Chemical compounds
MX2009006284A (es) Arilpirazoles sustituidos.
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
HK1082918A1 (en) Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis
TW200508199A (en) Novel compound
GEP20125392B (en) Tricyclic compounds and pharmaceutical use thereof
MX2010007269A (es) Derivado de 17-(1´-propenil)-17-3´-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen.
MX2009013629A (es) DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y EL MEDICAMENTO QUE CONTIENE EL DERIVADO.
WO2009083267A3 (de) Steroid-17,17-lactol-derivat, dessen verwendung und das derivat enthaltende arzneimittel
CO6321233A2 (es) Derivados 15, 16 -metilen-17-(`1`-propenil)-17-3´- oxidoestra -4- en -ona su uso y medicamento que lo contiene
ECSP10010318A (es) Derivado de -lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene
CU20100138A7 (es) Derivados de 17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal